Y Combinator

Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.

Forcyte Biotechnologies, Inc. was formed to leverage FLECS Technology (originally developed in the Di Carlo Lab @ UCLA) to provide drug-makers and researchers direct access to cellular force generation at the single-cell level – a cellular behavior that was previously inaccessible in an automated way.Forcyte Biotechnologies provide a fundamentally new class of cell-based assays that functionally evaluate single-cell contractility, integrated into standard multi-wellplate vessels – available both as end-to-end services, and as consumables.

Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Dnovobio is a developer of a direct reprogramming technology intended to create any cell, tissue, or organ on demand. Its company's platform converts skin into functional brain cells. The company is currently operating in Stealth mode.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.

Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.

Accelerating the discovery of immunotherapies

BluumBio develops cutting-edge bioremediation technologies and services, offering scalable solutions for companies of all sizes. BluumBio makes bacteria and plants eat toxic chemicals that clean up pollution.

Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Kuleana creates plant-based alternatives for people's seafood favorites, using plants and biotechnology without the environmental and ethical consequences.

Pipe | bio builds bioinformatics solutions to help optimize development of antibodies and antibody-like-therapeutics.

Entelexo Biotherapeutics develops treatments intended to assist in the treatment of immune-mediated diseases. Its treatment includes a new class of drugs which include extracellular vesicles (EVs) that are derived from stem cells, enabling healthcare workers to treat autoimmune diseases.

Orbillion Bio, Inc., a food-tech company, develops cultured meat products using a small tissue sample from heritage cattle breeds. It develops premium cell-based meat products from heritage cell lines that are directly sourced from farmers. The company was incorporated in 2019 and is based in Fremont, California.

Forcyte Biotechnologies, Inc. was formed to leverage FLECS Technology (originally developed in the Di Carlo Lab @ UCLA) to provide drug-makers and researchers direct access to cellular force generation at the single-cell level – a cellular behavior that was previously inaccessible in an automated way.Forcyte Biotechnologies provide a fundamentally new class of cell-based assays that functionally evaluate single-cell contractility, integrated into standard multi-wellplate vessels – available both as end-to-end services, and as consumables.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Pipe | bio builds bioinformatics solutions to help optimize development of antibodies and antibody-like-therapeutics.

Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease. The company's services allow healthcare providers to reduce their reliance on dialysis while also enhancing the disease status of renal patients through the combination of stem cell biology and bio-fabrication. Trestle Biotherapeutics was founded in 2020 by Alice Chen and Ben Shepherd and is based in San Diego, California, United States.

We are food-tech company. We developed proprietary protein texturing technology that enables us to produce plant-based whole cuts. Our vision is to produce a variety of meat products and match animal derived counterparts by taste, price and convenience. We want to accelerate transition of meat industry into a more sustainable future - by 2030 we want to cut meat consumption in half.

LiliumX discovers new bispecific antibodies against cancer by utilizing a protein technology platform to facilitate the scalable discovery of first-in-class bispecific biologics.

We are food-tech company. We developed proprietary protein texturing technology that enables us to produce plant-based whole cuts. Our vision is to produce a variety of meat products and match animal derived counterparts by taste, price and convenience. We want to accelerate transition of meat industry into a more sustainable future - by 2030 we want to cut meat consumption in half.

Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

Future Fields is a Canadian company dedicated to advancing cellular agriculture by creating accessible consumer products. The company specializes in developing cost-effective and serum-free growth media essential for the production of cultured meat. Additionally, Future Fields focuses on insect-based recombinant protein to enhance sustainability in protein production. By producing vital growth components for cell culture, the company aims to reduce the environmental impact of agriculture while maximizing social benefits. Through these innovations, Future Fields seeks to enable the agriculture industry to produce cell-based foods in a more efficient and sustainable manner.

Atom Bioworks specializes in developing a pattern-recognition-enabled sensing and therapeutics platform aimed at enhancing medical applications for the early diagnosis and treatment of infectious diseases and cancer. The company's innovative platform leverages computational biology, quantum chemistry, software, and machine learning to identify diseased surface protein patterns. By creating corresponding pattern-matching constructs, Atom Bioworks provides researchers with advanced nano-pattern recognition capabilities, ultimately facilitating improved diagnostic and therapeutic strategies in the medical field.

Boost Biomes, Inc. specializes in developing microbial products aimed at enhancing food production and shelf-life in agriculture. The company employs a discovery platform that leverages DNA sequencing, selective enrichment, and advanced informatics to swiftly and cost-effectively identify multi-microbial products with significant commercial applications. This innovative approach enables the identification of multi-microbial products, which are often more effective than traditional single microbe solutions, particularly in managing diseases affecting high-value crops. Founded in 2016 and based in South San Francisco, California, Boost Biomes was previously known as Coax Biosystems, Inc. before rebranding in May 2017.

Biocogniv Inc. specializes in developing artificial intelligence-powered diagnostic tools tailored for hospitals. Founded in 2019 and based in Burlington, Vermont, the company creates plugins for electronic health records (EHRs) that enhance clinical decision-making. Its initial product screens patients for COVID-19 by rapidly analyzing standard blood test results, achieving a sensitivity rate of 95%. Additionally, Biocogniv's technology aims to predict sepsis-related in-hospital mortality and the need for intensive care unit admission during emergency department visits. By seamlessly integrating with EHR workflows, Biocogniv's solutions facilitate accurate and non-invasive diagnostic methods, thereby improving patient outcomes and operational efficiency in the medical sector.

Biocogniv Inc. specializes in developing artificial intelligence-powered diagnostic tools tailored for hospitals. Founded in 2019 and based in Burlington, Vermont, the company creates plugins for electronic health records (EHRs) that enhance clinical decision-making. Its initial product screens patients for COVID-19 by rapidly analyzing standard blood test results, achieving a sensitivity rate of 95%. Additionally, Biocogniv's technology aims to predict sepsis-related in-hospital mortality and the need for intensive care unit admission during emergency department visits. By seamlessly integrating with EHR workflows, Biocogniv's solutions facilitate accurate and non-invasive diagnostic methods, thereby improving patient outcomes and operational efficiency in the medical sector.

Trident Bioscience, Inc., a biotechnology company, develops DNA library optimization software to accelerate custom protein development. Its software uses algorithm for degenerate codon selection which enables cost- and time-efficient library construction. The company’s software is also used to couple leading models of protein structure and function to optimized protocols for gene synthesis, expression, and screening to accelerate custom protein development. Trident Bioscience, Inc. was incorporated in 2020 and is based in Mountain View, California.

Hannah Life Technologies Pte. Ltd., founded in 2019 and based in Singapore, specializes in designing and developing innovative devices aimed at improving conception chances for couples during intercourse. The company seeks to transform the infertility treatment landscape by creating groundbreaking and safe fertility products that address significant unmet needs in this field. Guided by a Scientific Advisory Board composed of leading fertility clinicians, Hannah Life Technologies is committed to advancing solutions that enhance reproductive health and support individuals facing infertility challenges.

Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.

OpenBiome is a nonprofit organization dedicated to expanding safe access to fecal microbiota transplants (FMT), and to catalyzing research into the human microbiome. Founded by a team of doctors, scientists and public health advocates, OpenBiome has two primary objectives.

Future Fields is a Canadian company dedicated to advancing cellular agriculture by creating accessible consumer products. The company specializes in developing cost-effective and serum-free growth media essential for the production of cultured meat. Additionally, Future Fields focuses on insect-based recombinant protein to enhance sustainability in protein production. By producing vital growth components for cell culture, the company aims to reduce the environmental impact of agriculture while maximizing social benefits. Through these innovations, Future Fields seeks to enable the agriculture industry to produce cell-based foods in a more efficient and sustainable manner.

Kuleana creates plant-based alternatives for people's seafood favorites, using plants and biotechnology without the environmental and ethical consequences.

Boost Biomes, Inc. specializes in developing microbial products aimed at enhancing food production and shelf-life in agriculture. The company employs a discovery platform that leverages DNA sequencing, selective enrichment, and advanced informatics to swiftly and cost-effectively identify multi-microbial products with significant commercial applications. This innovative approach enables the identification of multi-microbial products, which are often more effective than traditional single microbe solutions, particularly in managing diseases affecting high-value crops. Founded in 2016 and based in South San Francisco, California, Boost Biomes was previously known as Coax Biosystems, Inc. before rebranding in May 2017.

Biobot Analytics is a wastewater epidemiology company that is transforming wastewater infrastructure into public health observatories. Its wastewater monitoring technology analyzes urine and stool samples to create a health database that is independent of hospital reporting systems, free from societal biases affecting who can and can’t seek care, and most importantly, rapidly adaptable to new and emerging public health threats.

AI for new drug discovery

Volumetric, Inc. develops bioprinting platform, which offers 3D bioprinters creating vascularized human tissue. It provides bioprinters and bio inks for applications in the life sciences, drug discovery, and medical devices. The company was incorporated in 2014 and is based in Houston, Texas.

Operator is building a low-code platform that makes it easy to build business applications. With Operator, analysts can build software solutions to common problems and bottlenecks without worrying about managing data or setting up integrations.

Abalone Bio, Inc. is a biotechnology company focused on developing antibody drugs for various medical conditions, including pain, inflammatory diseases, rare cancers, and rare kidney diseases. Founded in 2017 and based in Richmond, California, the company aims to create treatments for peripheral neuropathy. Abalone Bio employs advanced techniques such as yeast cell libraries to generate billions of antibody variants, which can either activate or inhibit specific drug targets. Additionally, the company utilizes gene sequencing, machine learning, and synthetic biology to produce recombinant protein versions of its antibodies and to validate their efficacy through human cell assays. This innovative approach allows Abalone Bio to address rare diseases with distinct mechanisms of action.

Dropprint Genomics Inc. develops a single cell genomics software to reduce the time/financial cost of analyzing individual cell activity to enable better drug discovery. Its software harnesses single-cell genomics and machine learning to build a personalized model of the immune system from a single blood draw. The company was incorporated in 2019 and is based in Oakland, California.

Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases. Felix Biotechnology's bio-therapeutics targets antibiotic-resistant bacteria to manage infectious diseases precisely and effectively, allowing healthcare professionals to manage urgent microbial challenges in human health.

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.

Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.

Arpeggio Biosciences, Inc. is a biotechnology company based in Boulder, Colorado, founded in 2017. It specializes in developing software that captures and analyzes cellular RNA activity through a unique combination of biological assays and machine learning algorithms. This technology allows for low-depth sequencing to generate high-resolution snapshots of cellular dynamics in response to drug treatments. By revealing the biological networks that influence a drug's function, Arpeggio's platform aids pharmaceutical and biotechnology companies in understanding the mechanisms behind therapeutics. The company’s approach enhances the identification of new drug targets and increases the likelihood of success in clinical advancements. Arpeggio Biosciences is composed of a diverse team of molecular biologists, computer scientists, and biotechnology enthusiasts dedicated to advancing the understanding of drug mechanisms.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Sequence Bio is a data-driven biotechnology company in Newfoundland and Labrador. We're leading the NL Genome Project, a large-scale genomics project studying Newfoundland’s unique genetic makeup by combining multi-omic data with longitudinal health records to improve how we understand, treat, and prevent disease. Our goal is to use data and new computational approaches to enable better healthcare and transform drug discovery.

Arpeggio Biosciences, Inc. is a biotechnology company based in Boulder, Colorado, founded in 2017. It specializes in developing software that captures and analyzes cellular RNA activity through a unique combination of biological assays and machine learning algorithms. This technology allows for low-depth sequencing to generate high-resolution snapshots of cellular dynamics in response to drug treatments. By revealing the biological networks that influence a drug's function, Arpeggio's platform aids pharmaceutical and biotechnology companies in understanding the mechanisms behind therapeutics. The company’s approach enhances the identification of new drug targets and increases the likelihood of success in clinical advancements. Arpeggio Biosciences is composed of a diverse team of molecular biologists, computer scientists, and biotechnology enthusiasts dedicated to advancing the understanding of drug mechanisms.

Boost Biomes, Inc. specializes in developing microbial products aimed at enhancing food production and shelf-life in agriculture. The company employs a discovery platform that leverages DNA sequencing, selective enrichment, and advanced informatics to swiftly and cost-effectively identify multi-microbial products with significant commercial applications. This innovative approach enables the identification of multi-microbial products, which are often more effective than traditional single microbe solutions, particularly in managing diseases affecting high-value crops. Founded in 2016 and based in South San Francisco, California, Boost Biomes was previously known as Coax Biosystems, Inc. before rebranding in May 2017.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.

Sequence Bio is a data-driven biotechnology company in Newfoundland and Labrador. We're leading the NL Genome Project, a large-scale genomics project studying Newfoundland’s unique genetic makeup by combining multi-omic data with longitudinal health records to improve how we understand, treat, and prevent disease. Our goal is to use data and new computational approaches to enable better healthcare and transform drug discovery.

Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradeable plastics and other high value materials. Genecis is headquartered in Scarborough, Canada.

Solugen, Inc. is a specialty chemicals manufacturer based in Houston, Texas, founded in 2016. The company utilizes industrial biotechnology and green chemistry to produce a range of eco-friendly industrial chemicals. Its product offerings include BioPeroxide, a carbon-negative hydrogen peroxide; BioChelate, a biodegradable chelant; ScavSol, a multivalent metal sequestrant for energy applications; ScaleSol, a scale control alternative to phosphonates; and CorrSol, designed for corrosion and fouling control. Solugen focuses on creating safe, cost-effective, and environmentally-friendly solutions, serving various sectors such as agriculture, cleaning, energy, and water. The company employs a patented method that leverages bio-inspired reactions and plant materials as low-cost feedstocks, enabling it to produce innovative products that are competitively priced in the market.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on engineering and developing tools for biological automation. Founded in 2018, the company specializes in creating scalable automation solutions for genetic engineering, aiming to enhance efficiency and precision in biological research and applications.

AI for new drug discovery

Synova Life Sciences is developing a novel non-enzymatic device to obtain stem cells from adipose tissue for medical research and therapy. They help physicians and patients harvest autologous stem cells and use their regenerative ability to enhance the quality of life. Synova Life Sciences is the winner of Cal State Fullerton Business Plan Competition 2013, MD&M West "Shark Tank" 2015, TriTech Funding the Big Idea 2015 and was the First Runner Up at TCVN Survivor 8. Synova Life Sciences was founded in 2013.

uBiome, Inc. is a microbial genomics company based in San Francisco, California, founded in 2012. The company specializes in developing sequencing-based clinical microbiome tests, which include SmartGut, a test that identifies pathogenic and commensal microorganisms linked to infections, and SmartJane, a women's health screening test that assesses multiple conditions such as HPV and STIs. Additionally, uBiome offers Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. The firm aimed to empower patients and healthcare providers by providing insights into the human microbiome and its impact on health. However, uBiome faced financial difficulties, filing for Chapter 11 bankruptcy in September 2019, which was subsequently converted to Chapter 7 on October 11, 2019.

Rejuvenation Technologies Inc. develops nucleoside-modified telomerase reverse transcriptase messenger ribonucleic acid to extend telomeres for human health extension. It offers cell therapies, which includes tissue engineering, tissue and cell transplants, skin grafts, immunotherapy, and regeneration medicine. The company was incorporated in 2016 and is based in Mountain View, California.

Data Driven Bioscience is a company based in Durham, North Carolina, that specializes in providing integrated kits and software designed for cancer diagnosis. Their products enable clinical laboratories to utilize genomics in the diagnosis and treatment of cancer. The kits are equipped to connect with machine learning software and a comprehensive database of cancer cases, allowing for the generation of detailed molecular reports for individual tumors. This innovative approach aims to enhance the accuracy and effectiveness of cancer diagnostics, facilitating better treatment decisions for patients.

Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

Cytera CellWorks, a biotechnology platform, builds machines that automate growing mammalian cells for biotech. Based in London, England, the company was founded by Ignacio Willats and Ali Afshar.

CB Therapeutics is a biotech company that specializes in the biosynthetic production of cannabinoids from sugar. CB Therapeutics produces pure cannabinoids like CBD and THC using yeast and sugar. No plants involved.

64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.

Perception Biosystems focuses on accelerating the clinical translation of gene therapies by innovating their development and manufacturing processes. Founded in 2018 and based in Palo Alto, California, the company creates advanced manufacturing systems that facilitate the quicker and more cost-effective production of gene therapies compared to traditional methods. This innovative approach enhances the quality and speed of pre-clinical research and clinical trials, thereby streamlining the pathway for gene therapies to reach patients more efficiently.

Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production. The company's throughput screening and strain construction facilitate the rapid optimization of pathways to convert cheap and renewable feedstock to high-value chemicals. Founded in 2011, Lygos is headquartered in Berkeley, California.

Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.

Macromoltek does computational drug discovery for pharma companies, focusing on antibodies for therapeutics and diagnostics. This mother-daughter team’s approach aims to make research for everything from flu to cancer treatments an order of magnitude faster. With an accelerated process to discover antibodies, medical researchers can (1) craft targeted treatment plans for previously undruggable targets and (2) overcome patients’ drug resistance, a major challenge when treating diseases caused by bacteria, viruses, and parasites.

Sixfold Bioscience is a preclinical-stage biotech company that engineers targeted therapeutic delivery systems. Their programmable oligonucleotide delivery systems are able to deliver gene therapy molecules exclusively to diseased cells. It also provides a solution to the drug delivery challenge, bringing cures for genetically-driven diseases to patients. Sixfold Bioscience was founded on 2017 and is headquartered in London.

Avro Life Science is a Canadian company focused on developing transdermal drug delivery systems, specifically medicated skin patches designed for the pediatric and elderly populations. Utilizing a novel biopolymer as a platform, Avro's technology enables passive delivery of small molecules and drugs directly into the bloodstream, allowing for a slow-release mechanism. This innovative approach aims to enhance medication accessibility while minimizing the impact on the liver, ultimately improving health outcomes and quality of life for its patients.

ZBiotics Company develops a genetically engineered probiotic drink. It offers ZBiotics, a drink that produces an enzyme that breaks down acetaldehyde, an unwanted byproduct of alcohol that accumulates in gut when alcohol is consumed. The company sells its products online. The company was incorporated in 2016 and is based in San Francisco, California.

Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.

Tradewind BioScience is a biotechnology company developing antibody therapeutics for ovarian cancer. Tradewind BioScience is building tools to attack highly aggressive and deadly human cancers.

Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.

BioRender is a Toronto-based company founded in 2017 that specializes in creating a web-based tool designed for scientists to produce high-quality scientific figures quickly and efficiently. The platform features a vast library of thousands of scientific icons and templates, enabling users to utilize a "drag-and-drop" functionality for easy illustration creation. BioRender aims to establish a standard visual language for biology, facilitating clearer communication within the scientific community. By providing accurate and accessible resources, the tool helps save time and costs for researchers and their collaborators, making the process of creating and sharing scientific visuals more streamlined and effective.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Solugen, Inc. is a specialty chemicals manufacturer based in Houston, Texas, founded in 2016. The company utilizes industrial biotechnology and green chemistry to produce a range of eco-friendly industrial chemicals. Its product offerings include BioPeroxide, a carbon-negative hydrogen peroxide; BioChelate, a biodegradable chelant; ScavSol, a multivalent metal sequestrant for energy applications; ScaleSol, a scale control alternative to phosphonates; and CorrSol, designed for corrosion and fouling control. Solugen focuses on creating safe, cost-effective, and environmentally-friendly solutions, serving various sectors such as agriculture, cleaning, energy, and water. The company employs a patented method that leverages bio-inspired reactions and plant materials as low-cost feedstocks, enabling it to produce innovative products that are competitively priced in the market.

Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance. Using Enzyme’s software, those companies can avoid spending money on costly consultants which in turn can reduce their compliance costs by up to 50 percent. Since 10 percent of all personnel in biopharma and life sciences companies are related to regulatory issues, it can lower headcount as well. Perhaps most importantly, Enzyme can also make it easier and faster for those companies to bring their products to market.

Modular Science aims to automate ninety nine percent of the processes involved in vegetable farming with modular machines for agriculture.

Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re already testing COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses.

MedTech is a professional community focused on advancing the bioscience and medical technology sectors. Founded in 2004 and based in Syracuse, New York, it provides platforms for professionals to connect, collaborate, and engage in education and advocacy. The organization hosts various events, including the MedTech Annual Conference and MedTech Annual Members' Dinner, which serve as networking and learning opportunities. Additionally, MedTech operates the MedTech Institute, offering training and certification programs aimed at enhancing skills within the industry. Through its comprehensive resources, including a dedicated website for news and updates, MedTech supports its members in navigating the evolving landscape of biotechnology and medical innovation.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Solugen, Inc. is a specialty chemicals manufacturer based in Houston, Texas, founded in 2016. The company utilizes industrial biotechnology and green chemistry to produce a range of eco-friendly industrial chemicals. Its product offerings include BioPeroxide, a carbon-negative hydrogen peroxide; BioChelate, a biodegradable chelant; ScavSol, a multivalent metal sequestrant for energy applications; ScaleSol, a scale control alternative to phosphonates; and CorrSol, designed for corrosion and fouling control. Solugen focuses on creating safe, cost-effective, and environmentally-friendly solutions, serving various sectors such as agriculture, cleaning, energy, and water. The company employs a patented method that leverages bio-inspired reactions and plant materials as low-cost feedstocks, enabling it to produce innovative products that are competitively priced in the market.

TL Biolabs Corp. is a biotechnology company based in Santa Clara, California, that specializes in automated genomic testing for livestock. Established in 2016, the company focuses on providing cost-effective genomic tests specifically for beef and dairy cattle. In addition to its testing services, TL Biolabs offers complimentary software designed to deliver actionable results, enhancing decision-making for livestock management.

Nephrogen is a biotechnology company dedicated to developing novel diagnostics and research tools for various life threatening diseases.

Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production. The company's throughput screening and strain construction facilitate the rapid optimization of pathways to convert cheap and renewable feedstock to high-value chemicals. Founded in 2011, Lygos is headquartered in Berkeley, California.

Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia creates engineered organisms that can be controlled with small molecules.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production. The company's throughput screening and strain construction facilitate the rapid optimization of pathways to convert cheap and renewable feedstock to high-value chemicals. Founded in 2011, Lygos is headquartered in Berkeley, California.

Cryopreserving people's healthy young cells for use with future medical technologies.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Industrial Microbes designs and builds microbes that produce better chemicals with lower costs and lower carbon emissions. We use greenhouse gases as the raw materials, including biogas, natural gas, and carbon dioxide. We scale our process with global chemical producers.

Strateos automates chemistry, biology, and tissue analysis into closed loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, we enable our pharmaceutical partners to more rapidly and efficiently discover new drug candidates. Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money. Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology. Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs. They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists.

Strateos automates chemistry, biology, and tissue analysis into closed loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, we enable our pharmaceutical partners to more rapidly and efficiently discover new drug candidates. Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money. Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology. Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs. They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists.

At 20n, They use algorithms to engineer microbes. Specifically, their algorithms engineer microbes to make chemicals. Like yeast produces alcohol during beer brewing, their engineered microbes will produce chemicals with therapeutic health and industrial biotech applications. The best illustration of this DARPA-backed technology is the bacteria They engineered to produce Paracetamol (also known as acetaminophen, and sold under the brand name Tylenol). Aside from this bacteria, there is no known natural way of producing acetaminophen. They are building data mining technology that will allow us to enable the bioproduction of a whole spectrum of valuable molecules. Below is the map of every chemical that can be made biologically, as discovered by 20n's algorithms.

uBiome, Inc. is a microbial genomics company based in San Francisco, California, founded in 2012. The company specializes in developing sequencing-based clinical microbiome tests, which include SmartGut, a test that identifies pathogenic and commensal microorganisms linked to infections, and SmartJane, a women's health screening test that assesses multiple conditions such as HPV and STIs. Additionally, uBiome offers Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. The firm aimed to empower patients and healthcare providers by providing insights into the human microbiome and its impact on health. However, uBiome faced financial difficulties, filing for Chapter 11 bankruptcy in September 2019, which was subsequently converted to Chapter 7 on October 11, 2019.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

TAXA Biotechnologies enable cheaper, faster, and better genetic engineering of plants. They offer our platform both as a service to other companies and use it internally to develop our own engineered plants. We make money from platform access service fees and from royalties on the sale of the final products. Our first product is a Glowing Plant, which was the first Kickstarter for a synthetic biology application earning us over $600k in pre-orders. We are also close to shipping a Fragrant Moss.